|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
118,610,000 |
Market
Cap: |
23.41(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.1974 - $0.2732 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Oncocyte is a molecular diagnostics company focused on developing and commercializing proprietary laboratory-developed tests to serve unmet medical needs across the cancer care continuum. Co.'s DetermaRx is a predictive molecular test for early-stage adenocarcinoma of the lung. This test provides information that a physician can use to help identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer who are at high-risk of recurrence and may benefit from chemotherapy. Co.'s portfolio includes a gene expression-based test called DetermaIO, which is being developed to identify patients most likely to respond to immunotherapy drugs.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
2,457,288 |
2,457,288 |
2,487,288 |
30,608,426 |
Total Buy Value |
$7,167,688 |
$7,167,688 |
$7,174,135 |
$15,854,134 |
Total People Bought |
3 |
3 |
4 |
10 |
Total Buy Transactions |
4 |
4 |
5 |
20 |
Total Shares Sold |
0 |
0 |
0 |
107,514 |
Total Sell Value |
$0 |
$0 |
$0 |
$111,901 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Andrews Ronald Asbury |
CEO and President |
|
2020-03-30 |
4 |
B |
$2.26 |
$61,454 |
D/D |
27,216 |
44,698 |
2.81 |
-14% |
|
Levine Mitchell S |
Chief Financial Officer |
|
2020-03-14 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,916) |
26,579 |
|
- |
|
Levine Mitchell S |
Chief Financial Officer |
|
2020-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
33,495 |
|
- |
|
Kamen Efrem |
10% Owner |
|
2020-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
12,223,953 |
|
-2% |
|
Biotime Inc |
Previous 10% Owner |
|
2020-01-02 |
4 |
S |
$2.16 |
$5,137,942 |
D/D |
(2,383,090) |
6,041,154 |
|
-36% |
|
Bradsher Neal C |
10% Owner |
|
2020-01-02 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
13,666,204 |
1.42 |
36% |
|
Bradsher Neal C |
10% Owner |
|
2020-01-02 |
4 |
B |
$2.16 |
$3,000,001 |
D/D |
1,391,466 |
13,666,204 |
2.45 |
36% |
|
Arno Andrew |
Director |
|
2019-09-17 |
4 |
B |
$2.16 |
$108,130 |
D/D |
50,000 |
102,447 |
2.39 |
- |
|
Kalajian Tony T |
SVP-Chief Accounting Officer |
|
2019-09-13 |
4 |
B |
$1.98 |
$19,800 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
Levine Mitchell S |
CFO |
|
2019-09-12 |
4/A |
B |
$2.01 |
$20,060 |
D/D |
10,000 |
13,495 |
2.74 |
- |
|
Levine Mitchell S |
Chief Financial Officer |
|
2019-09-12 |
4 |
B |
$2.01 |
$20,060 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
Biotime Inc |
10% Owner |
|
2019-09-11 |
4 |
S |
$1.66 |
$6,640,000 |
D/D |
(4,000,000) |
8,424,244 |
|
- |
|
Bradsher Neal C |
10% Owner |
|
2019-09-11 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
11,098,267 |
1.42 |
- |
|
Bradsher Neal C |
10% Owner |
|
2019-09-11 |
4 |
B |
$1.66 |
$3,320,000 |
D/D |
2,000,000 |
11,098,267 |
2.45 |
- |
|
Biotime Inc |
10% Owner |
|
2019-07-05 |
4 |
S |
$2.00 |
$4,500,000 |
D/D |
(2,250,000) |
12,424,244 |
|
- |
|
Bradsher Neal C |
10% Owner |
|
2019-07-02 |
4 |
B |
$2.00 |
$0 |
I/I |
0 |
9,098,267 |
1.42 |
- |
|
Bradsher Neal C |
10% Owner |
|
2019-07-02 |
4 |
B |
$2.00 |
$2,000,000 |
D/D |
1,000,000 |
9,098,267 |
2.45 |
- |
|
Bradsher Neal C |
10% Owner |
|
2019-02-08 |
4 |
B |
$3.75 |
$0 |
I/I |
0 |
8,098,267 |
1.42 |
- |
|
Bradsher Neal C |
10% Owner |
|
2019-02-08 |
4 |
B |
$3.75 |
$1,999,999 |
D/D |
533,333 |
8,098,267 |
2.45 |
- |
|
Redmond Cavan M. |
Director |
|
2018-07-26 |
4 |
B |
$0.00 |
$0 |
D/D |
52,447 |
52,447 |
2.31 |
- |
|
Annett William |
President and CEO |
|
2018-07-26 |
4 |
B |
$0.00 |
$0 |
D/D |
3,500 |
3,500 |
2.73 |
- |
|
Andrews Ronald Asbury |
Director |
|
2018-07-26 |
4 |
B |
$0.00 |
$0 |
D/D |
17,482 |
17,482 |
2.31 |
- |
|
Arno Andrew |
Director |
|
2018-07-26 |
4 |
B |
$0.00 |
$0 |
D/D |
52,447 |
52,447 |
2.31 |
- |
|
Levine Mitchell S |
Chief Financial Officer |
|
2018-07-26 |
4 |
B |
$0.00 |
$0 |
D/D |
3,495 |
3,495 |
2.66 |
- |
|
Last Andrew J. |
Director |
|
2018-07-26 |
4 |
B |
$0.00 |
$0 |
D/D |
6,993 |
6,993 |
2.31 |
- |
|
142 Records found
|
|
Page 5 of 6 |
|
|